Abstract
Excessive glial activation, with overproduction of cytokines and oxidative stress products, is detrimental and a hallmark of neurodegenerative disease pathology. Suppression of glial activation is a potential therapeutic approach, and protein kinases are targets of some antiinflammatory drugs. To address an unmet need for selective inhibitors of glial activation, we developed a novel 3-amino-6-phenylpyridazine derivative that selectively blocks increased IL-1β, iNOS, and NO production by activated glia, without inhibition of potentially beneficial glial functions.
Original language | English (US) |
---|---|
Pages (from-to) | 563-566 |
Number of pages | 4 |
Journal | Journal of Medicinal Chemistry |
Volume | 45 |
Issue number | 3 |
DOIs | |
State | Published - Jan 31 2002 |
Funding
ASJC Scopus subject areas
- Drug Discovery
- Molecular Medicine